

TITLE	PHASE	APPROVAL DATE	STATUS
MMCIRB 2013-059 A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes) in Refractory Patients with Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver	I	NOV/11/2013	APPROVED ONGOING
MMCIRB 2015-056 A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Autologous Dendritic Cell Immunotherapy for Cancer Patients: A Registry Study	I	FEB/16/2016	APPROVED ONGOING
MMCIRB 2018-033 A Phase III, Randomized, Placebo-Controlled, Double Blind, Multi-Center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer Stage III) (PACIFIC 2)	III	JUN/07/2018	APPROVED ONGOING
MMCIRB 2018-088 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Doublet Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer Subjects (CANOPY-1)	III	FEB/16/2019	APPROVED ONGOING
MMCIRB 2018-089 A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)	III	MAR/26/2019	APPROVED ONGOING
MMCIRB 2018-099 A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-Small Cell Lung Cancer (AEGEAN)	III	APR/01/2021	APPROVED ONGOING
MMCIRB 2018-100 A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women with Locally Advanced Cervical Cancer (CALLA)	III	MAR/04/2019	APPROVED ONGOING
MMCIRB 2019-055/ SJREB 2019-32 A Randomized, Double-Blind, Parallel Group, Equivalence, multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients with Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer	III	JAN/23/2020	APPROVED ONGOING
MMCIRB 2019-114/ SJREB 2019-58 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Pegcetacoplan Nocturnal Hemoglobinuria (PNH)	III	APR/05/2020	APPROVED ONGOING
MMCIRB 2020-008/ SJREB 2020-27 A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia	III	MAY/18/2020	APPROVED ONGOING
MMCIRB 2020-019 A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum	III	JUN/22/2020	APPROVED ONGOING
MMCIRB 2020-030/ SREB 2020 - 20 Public Health Emergency: Solidarity Trial An International randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care	I	APR/18/2020	APPROVED ONGOING
MMCIRB 2020-064 Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct	I	AUG/18/2020	APPROVED ONGOING

MMCIRB 2020-076/ SJREB 2020 - 63 A Randomized, Double-blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA0012 in First-Line Metastatic Squamous and NonSquamous Non-Small Cell Lung Cancer (POD1UM-304)	III	OCT/30/2020	APPROVED ONGOING
MMCIRB 2020-079 A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First Line Metastatic Squamous and Non Squamous Non-Small Cell Lung Cancer	III	NOV/09/2020	APPROVED ONGOING
MMCIRB 2020-088 / SJREB 2020 - 48 A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)	II B	AUG/11/2020	APPROVED ONGOING
MMCIRB 2020-094/ SJREB2020-59 A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group study to evaluate the efficacy and safety of Dapirolizumab Pegol in study participants with moderately to severely active Systemic Lupus Erythematosus	III	OCT/17/2020	APPROVED ONGOING
MMCIRB 2020-131/ SJREB2020-087 A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- mediated COVID-19 in Participants Aged 12 Years and Older	II/III	DEC/20/2020	APPROVED ONGOING
MMCIRB 2020-151 / SJREB 2020 -102 A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients	III	APR/06/2021	APPROVED ONGOING
MMCIRB 2021-002/ SJREB2021-01 A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	III	JAN/25/2021	APPROVED ONGOING
MMCIRB 2021-024 (SJREB 2021-16) Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) CpG/alum	II and III	APR/14/2021	APPROVED ONGOING
MMCIRB 2021-052/ SJREB-2021-35 A multi-national, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older	III	JUN/29/2021	APPROVED ONGOING
MMCIRB 2021-054/ SJREB-2021-36 A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells) for the Prevention of COVID- 19 in Adults Aged 18 Years and Older	II	JUN/29/2021	APPROVED ONGOING
MMCIRB 2021-055/ SJREB-2021-36 A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells) for the Prevention of COVID- 19 in Adults Aged 18 Years and Older	II	JUN/29/2021	APPROVED ONGOING
MMCIRB 2021-078/ SJREB 2021 -101 A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase	II	SEP/28/2021	APPROVED ONGOING
MMCIRB 2021-089/ SJREB 2021-43 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis - APEX	III B	JUL/13/2021	APPROVED ONGOING
MMCIRB 2021-091/ SJREB 2021-53A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older	III	JUL/30/2021	APPROVED ONGOING

MMCIRB 2021-094/ SJREB 2021-58 Solidarity Vaccines Trial in the Philippines: Randomized Trial of Candidate Vaccines for COVID-19	III	AUG/06/2021	APPROVED ONGOING
MMCIRB 2021-097 (SJREB 2021-64) A Global, Multi-center, Randomized, Double-Blind, Placebo controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older	III	AUG/03/2021	APPROVED ONGOING
MMCIRB 2021-115 Observational, single arm, prospective study to evaluate the effectiveness of Legalon® in addition to diet and exercise in reducing plasma levels of liver enzymes in patients with non-alcoholic fatty liver disease and concomitant metabolic syndrome	IV	JAN/05/2022	Approved Ongoing
MMCIRB 2021-129 A Phase III, Open-label, Randomized study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib alone in Hepatocellular Carcinoma previously treated with Atezolizumab and Bevacizumab	Clinical Trial	OCT/27/2021	APPROVED ONGOING
MMCIRB 2021-163 A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Clinical Trial	DEC/01/2021	APPROVED ONGOING
MMCIRB2021-171 / SJREB 2022-01 EffisayITM ON: An open-label, long term extension study to assess the safety and efficacy of spesolimab treatment in patients with Generalized Pustular Psoriasis (GPP)	Clinical Trial	MAY/04/2022	APPROVED ONGOING
MMCIRB2021-173 A Phase 2, Single-Blinded, Randomised, Controlled Multi-Country Study to Evaluate the Safety, Reactogenicity, Efficacy and Immune Response following Sequential Treatment with an Anti-sense Oligonucleotide (ASO) against Chronic Hepatitis B (CHB) followed by Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients receiving Nucleos(t)ide Analogue (NA) Therapy	Clinical Trial	FEB/03/2022	APPROVED ONGOING
MMCIRB 2022-013 A Single-Arm, Phase 1b, Open-Label Study to Assess the Safety, Tolerability, and Pharmacodynamics of Repeat-Doses of Subcutaneous ANX009 with Standard of Care Therapy in Adult Participants with Lupus Nephritis	I B	MAR/28/2022	APPROVED ONGOING
MMCIRB 2022-044 A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension	II B	MAY/24/2022	APPROVED ONGOING
MMCIRB 2022-052 A Phase 2, Randomized, Double-blind, Placebo- controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection	II	JUL/05/2022	APPROVED ONGOING
MMCIRB 2022-074 A Phase III, Randomized, Open-Label, Sponsor- Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)	III	AUG/24/2022	APPROVED ONGOING
MMCIRB 2022-142/ SJREB 2022-90 Postmarketing Safety Experience Of Edoxaban For The Prevention Of Stroke And Systemic Embolism In Adult Patients With Nonvalvular Atrial Fibrillation (NVAf)	IV	MAR/20/2023	APPROVED ONGOING
MMCIRB 2022-153 An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long- Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension	II/III	MAR/26/2023	APPROVED ONGOING
MMCIRB 2022-157 A Randomized, Observer-Blinded, Active- Controlled, Phase I Study to Evaluate the Safety and Immunogenicity of the Recombinant Zoster Vaccine (CHO cell) in Healthy Adults Aged 40 Years and Older	I	JAN/11/2023	APPROVED ONGOING

MMCIRB 2022-158 A Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2)	III	JAN/12/2023	APPROVED ONGOING
MMCIRB 2022-169/ SJREB 2021-43 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis	III B	DEC/14/2022	APPROVED ONGOING
MMCIRB 2022-171 A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety, and Immunogenicity of a Booster Dose of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Adults ≥ 18 Years Old Who Received 2 or more doses of Inactivated COVID-19 Vaccine	II/III	DEC/14/2022	APPROVED ONGOING
MMCIRB 2022-175/ SJREB 2022-79 A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination	III	JAN/20/2023	APPROVED ONGOING
MMCIRB 2022-178/ SJREB 2022-122 A Phase I-II, double-blind, randomized, placebo-controlled study of a T cell priming next-generation vaccine against Coronavirus disease in healthy adults	I/II	MAY/09/2023	APPROVED ONGOING
MMCIRB 2023 -013/ SJREB 2023-09 A Randomized, Observer-Blind, Active Control Phase II Study to Evaluate the Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (Wgv-0129) as a Booster Dose in Healthy People Aged 18 Years and Older	II	MAY/23/2023	APPROVED ONGOING
MMCIRB 2023 -015/ SJREB 2022-24 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy	III	JUN/12/2023	APPROVED ONGOING
MMCIRB 2023 -016/ SJREB 2022-21 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy	III	JUN/12/2023	APPROVED ONGOING
MMCIRB 2023 -026/ SJREB 2022-53 An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V	II	AUG/17/2023	APPROVED ONGOING
MMCIRB 2023-027/ SJREB 2023-22 A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment with Regimens Containing Bedaquiline, OPC 167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults with Pulmonary Tuberculosis	II B/II C	JUN/13/2023	APPROVED ONGOING
MMCIRB 2023-031 A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment with Tigulixostat in Gout Patients with Hyperuricemia	III	APR/25/2023	APPROVED ONGOING
MMCIRB 2023-053 A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)	III	JUL/31/2023	APPROVED ONGOING
MMCIRB 2023-065 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease	III	FEB/01/2024	APPROVED ONGOING

MMCIRB 2023-083 A phase 2, partially-blinded, randomised trial assessing the safety and efficacy of TBAJ876 or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis.	II	AUG/16/2023	APPROVED ONGOING
MMCIRB 2023-087 An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X)	III	AUG/31/2023	APPROVED ONGOING
MMCIRB 2023-099 A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment with Tigulixostat in Gout Patients with Hyperuricemia	III	JUN/30/2023	APPROVED ONGOING
MMCIRB 2023-102/ SJREB 2023-84 A multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison trial to investigate the efficacy and safety of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia	III	OCT/05/2023	APPROVED ONGOING
MMCIRB 2023-109 A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants with Systemic Lupus Erythematosus	III	SEP/04/2023	APPROVED ONGOING
MMCIRB 2023-116/ SJREB 2022-76 A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age	III/ IIIB	OCT/19/2023	APPROVED ONGOING
MMCIRB 2023-122 Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analoguetreated Participants with Chronic Hepatitis B Virus (B-Well 2)	III	DEC/04/2023	APPROVED ONGOING
MMCIRB 2023-132 Post-marketing observational study on safety and efficacy of Omidenepag isopropyl (EYBELIS) ophthalmic solution in Filipino patients with glaucoma or ocular hypertension	IV	DEC/11/2023	APPROVED ONGOING
MMCIRB 2023-149 A Phase II Randomized, Open-Label Trial of a Six-Month Regimen of High -Dose Rifampicin, High Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis	II	MAY/03/2024	APPROVED ONGOING
MMCIRB 2023-152 An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies	I and II	NOV/06/2023	APPROVED ONGOING
MMCIRB 2023-154/ SJREB 2023-67 A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older	III	JAN/04/2024	APPROVED ONGOING
MMCIRB 2023-166/ SJREB 2023-100 A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate the Immunogenicity and Safety of the preventive COVID-19 vaccine AdCLDCoV19-1 OMI administered as a booster to Adults aged 19 years old and above	III	FEB/20/2024	APPROVED ONGOING
MMCIRB 2023-169 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Nonsquamous Non-small Cell Lung Cancer	III	MAY/03/2024	APPROVED ONGOING
MMCIRB2023-178/ SJREB 2023-115 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma	III	APR/24/2024	APPROVED ONGOING

MMCIRB2024-01-001/SJREB 2024-02 A randomized, double-blind, parallel-group study to compare efficacy, safety, and immunogenicity of GME751 proposed pembrolizumab biosimilar) and EUauthorized Keytruda® in adult participants with untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)	II	JUN/05/2024	APPROVED ONGOING
MMCIRB2024-04-055/ SJREB 2024-25 A Phase III Open-Label Extension Study to Evaluate the Long Term Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease	III	AUG/24/2024	APPROVED ONGOING
MMCIRB2024-04-061/ SJREB 2024-30 A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants as Primary Series At 2, 4, 6 Months of Age	II	JUL/24/2024	APPROVED ONGOING
MMCIRB 2024-04-064 A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Early-stage Non squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy	III	SEP/23/2024	APPROVED ONGOING
MMCIRB2024-04-066 Platform Assessing Regimens And Durations In a Global Multisite consortium for TB (PARADIGM4TB)	II	SEP/06/2024	APPROVED ONGOING
MMCIRB2024-05-078 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)	II	JAN/20/2025	APPROVED ONGOING
MMCIRB 2024-06-087 A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection	I B	AUG/19/2024	APPROVED ONGOING
MMCIRB2024-07-113 A Phase 2a/2b Randomized, Placebo-Controlled Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB	IIA, IIB	JUN/17/2025	APPROVED ONGOING
MMCIRB2024-011-139/ SJREB-2025-02 Randomized, Multicenter, Multinational, Double Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) versus Keytruda® in Combination with Chemotherapy for the Treatment of Patients with Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)	II	APRR/08/2025	APPROVED ONGOING
MMCIRB2024-011-141 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy	III	FEB/12/2025	APPROVED ONGOING
MMCIRB2024-011-144 Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB)	II	JAN/125/2025	APPROVED ONGOING
MMCIRB2024-011-145 A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination With a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis	II	DEC/23/2024	APPROVED ONGOING

MMCIRB2024-011-146 Prospective, Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB	II	JAN/08/2025	APPROVED ONGOING
MMCIRB2024-012-158/ SJREB 2025-18 A prospective, multi-national, multi-center, open-label, randomized, active-controlled, parallel-group, operationally seamless Phase II/III clinical study to evaluate the immunogenicity, safety and lot-to-lot consistency of LBVD, a fully liquid hexavalent diphtheria–tetanus–whole cell pertussis–hepatitis B-poliovirus (inactivated)-Haemophilus influenzae type b conjugate (DTwP-HepB-IPV-Hib) vaccine, compared to co-administration of DTwP-HepB-Hib vaccine and IPV vaccine in healthy infants at 6-, 10-, and 14-week of age as primary series.	III	APR/29/2025	APPROVED ONGOING
MMCIRB2025-02-033 Platform Assessing Regimens And Durations in a Global Multisite consortium for TB A Seamless Phase 2B/2C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis	IIB, IIC	APR/25/2025	APPROVED ONGOING
MMCIRB2025-02-034 Performance of STANDARD™ M10 MTB-RIF/INH vs. Xpert® MTB/RIF Ultra in Detecting Mycobacterium tuberculosis Among Presumptive Pulmonary TB Cases in a High TB Burden Country	IIB, IIC	MAR/29/2025	APPROVED ONGOING
MMCIRB2025-04-55/ SJREB 2025-43 DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	III	SEP/10/2025	APPROVED ONGOING
MMCIRB2025-04-56 A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy	III	JUN/08/2025	APPROVED ONGOING
MMCIRB2025-05-68/SJREB 2025-41 A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpropimexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)	III	JUL/01/2025	APPROVED ONGOING
MMCIRB2025-06-83 A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug resistant Pulmonary Tuberculosis	III	AUG/19/2025	APPROVED ONGOING
MMCIRB2025-06-84 A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug resistant Pulmonary Tuberculosis	III	AUG/19/2025	APPROVED ONGOING